121 related articles for article (PubMed ID: 3539147)
1. Structure-function relationships of shortened [LeuB25]insulins, semisynthetic analogues of a mutant human insulin.
Fischer WH; Saunders D; Brandenburg D; Diaconescu C; Wollmer A; Dodson G; De Meyts P; Zahn H
Biol Chem Hoppe Seyler; 1986 Sep; 367(9):999-1006. PubMed ID: 3539147
[TBL] [Abstract][Full Text] [Related]
2. A shortened insulin with full in vitro potency.
Fischer WH; Saunders D; Brandenburg D; Wollmer A; Zahn H
Biol Chem Hoppe Seyler; 1985 May; 366(5):521-5. PubMed ID: 3890892
[TBL] [Abstract][Full Text] [Related]
3. Semisynthesis and biological activity of porcine [LeuB24]insulin and [LeuB25]insulin.
Tager H; Thomas N; Assoian R; Rubenstein A; Saekow M; Olefsky J; Kaiser ET
Proc Natl Acad Sci U S A; 1980 Jun; 77(6):3181-5. PubMed ID: 6997872
[TBL] [Abstract][Full Text] [Related]
4. Structure-function relationships of des-(B26-B30)-insulin.
Spoden M; Gattner HG; Zahn H; Brandenburg D
Int J Pept Protein Res; 1995; 46(3-4):221-7. PubMed ID: 8537175
[TBL] [Abstract][Full Text] [Related]
5. Shortened insulin analogues: marked changes in biological activity resulting from replacement of TyrB26 and N-methylation of peptide bonds in the C-terminus of the B-chain.
Záková L; Barth T; Jirácek J; Barthová J; Zórad S
Biochemistry; 2004 Mar; 43(8):2323-31. PubMed ID: 14979729
[TBL] [Abstract][Full Text] [Related]
6. Shortened insulin with enhanced in vitro potency.
Casaretto M; Spoden M; Diaconescu C; Gattner HG; Zahn H; Brandenburg D; Wollmer A
Biol Chem Hoppe Seyler; 1987 Jun; 368(6):709-16. PubMed ID: 3304338
[TBL] [Abstract][Full Text] [Related]
7. Semisynthetic des-(B27-B30)-insulins with modified B26-tyrosine.
Lenz V; Gattner HG; Sievert D; Wollmer A; Engels M; Höcker H
Biol Chem Hoppe Seyler; 1991 Jul; 372(7):495-504. PubMed ID: 1930732
[TBL] [Abstract][Full Text] [Related]
8. In vivo metabolic activity of des-(B26-B30)-insulin-B25-amide and related analogues in the rat.
Stümpel F; Hartmann H; Brandenburg D; Creutzfeldt W
Diabetes Res Clin Pract; 1990 Jul; 9(3):257-64. PubMed ID: 2226126
[TBL] [Abstract][Full Text] [Related]
9. [LeuB24]- and [LeuB25]insulins are not antagonists of lipogenesis in adipocytes.
Diaconescu C; Saunders D; Gattner HG; Brandenburg D
Hoppe Seylers Z Physiol Chem; 1982 Feb; 363(2):187-92. PubMed ID: 7037593
[TBL] [Abstract][Full Text] [Related]
10. Role of the phenylalanine B25 side chain in directing insulin interaction with its receptor. Steric and conformational effects.
Nakagawa SH; Tager HS
J Biol Chem; 1986 Jun; 261(16):7332-41. PubMed ID: 3519607
[TBL] [Abstract][Full Text] [Related]
11. Mutations at the dimer, hexamer, and receptor-binding surfaces of insulin independently affect insulin-insulin and insulin-receptor interactions.
Shoelson SE; Lu ZX; Parlautan L; Lynch CS; Weiss MA
Biochemistry; 1992 Feb; 31(6):1757-67. PubMed ID: 1737029
[TBL] [Abstract][Full Text] [Related]
12. Semisynthesis and biological properties of the [B24-leucine]-, [B25-leucine[- and [B24-leucine, B25-leucine]-analogues of human insulin.
Inouye K; Watanabe K; Tochino Y; Kanaya T; Kobayashi M; Shigeta Y
Experientia; 1981; 37(8):811-3. PubMed ID: 7026270
[TBL] [Abstract][Full Text] [Related]
13. Enzyme-assisted semisynthesis of shortened B26-modified insulins.
Sievert D; Gattner HG; Lenz V; Höcker H
Biomed Biochim Acta; 1991; 50(10-11):S197-200. PubMed ID: 1820045
[TBL] [Abstract][Full Text] [Related]
14. Semisynthetic insulin analogues modified in positions B24, B25 and B29.
Svoboda I; Brandenburg D; Barth T; Gattner HG; Jirácek J; Velek J; Bláha I; Ubik K; Kasicka V; Pospísek J
Biol Chem Hoppe Seyler; 1994 Jun; 375(6):373-8. PubMed ID: 7980868
[TBL] [Abstract][Full Text] [Related]
15. Two mutant forms of human insulin. Structural consequences of the substitution of invariant B24- or B25-phenylalanine by leucine.
Wollmer A; Strassburger W; Glatter U; Dodson GG; McCall M; Gattner HG; Danho W; Brandenburg D; Rittel W
Hoppe Seylers Z Physiol Chem; 1981 Jun; 362(6):581-91. PubMed ID: 7024084
[TBL] [Abstract][Full Text] [Related]
16. Preparation and biological properties of [LeuB24, LeuB25]human insulin.
Jonczyk A; Keefer LM; Naithani VK; Gattner HG; De Meyts P; Zahn H
Hoppe Seylers Z Physiol Chem; 1981 May; 362(5):557-61. PubMed ID: 7019034
[No Abstract] [Full Text] [Related]
17. An insulin analogue possessing higher in vitro biological activity than receptor binding affinity. [21-Proline-B]insulin.
Schwartz GP; Burke GT; Chanley JD; Katsoyannis PG
Biochemistry; 1983 Sep; 22(19):4561-7. PubMed ID: 6354263
[TBL] [Abstract][Full Text] [Related]
18. The role of the C-terminus of the insulin B-chain in modulating structural and functional properties of the hormone.
Leyer S; Gattner HG; Leithäuser M; Brandenburg D; Wollmer A; Höcker H
Int J Pept Protein Res; 1995 Nov; 46(5):397-407. PubMed ID: 8567184
[TBL] [Abstract][Full Text] [Related]
19. Characteristics of binding of a low affinity, noncooperative insulin [( LeuB25]insulin) to IM-9 lymphocytes.
Green A; Frank BH; Rubenstein A; Tager H; Olefsky JM
Endocrinology; 1983 Dec; 113(6):1963-71. PubMed ID: 6357764
[TBL] [Abstract][Full Text] [Related]
20. Disposition of the phenylalanine B25 side chain during insulin-receptor and insulin-insulin interactions.
Mirmira RG; Tager HS
Biochemistry; 1991 Aug; 30(33):8222-9. PubMed ID: 1868095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
